PubMed-compiled information sheet
This sheet was compiled from PubMed (NIH) abstracts using AI assistance. Every factual claim is cited to a real PubMed article (see the source list). It has not yet been human-reviewed — confirm with a healthcare provider before use.
Compiled from 8 PubMed articles · model: gemma4:31b
Summary
Background
Traditional uses
Clinical evidence
Freeze-dried extracts demonstrated hypoglycemic, hypolipidemic, and hypoinsulinemic activity in a rat model [PMID:31369832].
PHELA (a combination containing R. myricoides) inhibited >90% of SARS-CoV-2 and SARS-CoV infection and nearly 100% of MERS-CoV infection in vitro [PMID:35718800].
Extracts of R. myricoides appeared to have antimutagenic properties in in vitro tests [PMID:18602977].
PHELA (a combination containing R. myricoides) is described as a safe and effective immune booster in pre-clinical and clinical studies [PMID:28473245].
Safety & adverse effects
Evidence summary
PubMed sources
- 1.PMID: 34435124 (2021) — The complete chloroplast genome sequence of Rotheca myricoides (Hochst.) Steane & Mabb., a traditional medicinal plant. · Mitochondrial DNA. Part B, Resources
- 2.PMID: 27830941 (2016) — 'The child that tiire doesn't give you, God won't give you either.' The role of Rotheca myricoides in Somali fertility practices. · Anthropology & medicine
- 3.PMID: 35718800 (2022) — In vitro study on efficacy of PHELA, an African traditional drug against SARS-CoV-2. · Scientific reports
- 4.PMID: 31369832 (2019) — The freeze-dried extracts of Rotheca myricoides (Hochst.) Steane & Mabb possess hypoglycemic, hypolipidemic and hypoinsulinemic on type 2 diabetes rat model. · Journal of ethnopharmacology
- 5.PMID: 18602977